RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. - Wikidata - awgldk - TriplyDB

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

http://www.wikidata.org/entity/Q46212098

about

Relationship between serum RANKL and RANKL in bone Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.A novel in vivo gene transfer technique and in vitro cell based assays for the study of bone loss in musculoskeletal disorders A roadmap to the brittle bones of cystic fibrosis.Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice.The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model.Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice Possible antiosteoporotic mechanism of Cicer arietinum extract in ovariectomized rats RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.Characterization of Regulatory Extracellular Vesicles from Osteoclasts.Commitment to the osteoblast lineage is not required for RANKL gene expression.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice.RANKL inhibition for the management of patients with benign metabolic bone disorders.Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.Skeletal and extraskeletal actions of denosumab.Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities.Locally limited inhibition of bone resorption and orthodontic relapse by recombinant osteoprotegerin protein.Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability.Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice.High fat diet attenuates hyperglycemia, body composition changes, and bone loss in male streptozotocin-induced type 1 diabetic mice.Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats.Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice.β‑Ecdysterone promotes autophagy and inhibits apoptosis in osteoporotic rats.IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.Analysis of early stage osteonecrosis of the human femoral head and the mechanism of femoral head collapse.Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study.Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.A Clinical Study Evaluating the Effects of Fluvastatin on Serum Osteoprotegerin Levels in Rheumatoid Arthritis Patients.Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats.

P2860

Q28245828-17321C1C-F13D-4218-B7E5-8B658DA716DC Q34107428-3E50237B-64DE-4B31-8FFB-91478251D66C Q34149279-A536EC60-26B0-44DB-B3E7-F732CC2F384B Q34299772-61183A16-4007-466A-936B-6AB1DCDF882E Q34442832-0C2C6C8E-131C-48D0-A438-7DEB9109F7E2 Q35070894-22364411-ABDE-4F63-87A5-F40DAF457DDD Q35080134-02C45206-F49B-4E2D-A6BC-0C5507E7EDE9 Q35096719-72A58991-9CEF-41D0-9AA5-23B3A30EB7A4 Q35175707-7C763750-510B-4FF1-A5E5-4CC1337853A8 Q35631694-C3A2CD66-3C6B-400C-8DFC-7ABBB685C51E Q35670191-AF15CFB0-5C09-4826-8C4A-DF2B8229FE28 Q35766784-7317548C-0AF4-49DD-99F5-9DCF65B40823 Q36326306-94AB48C1-36A7-4DBE-A5A7-04CACFB79593 Q37046045-16D29DA9-FDEE-48D6-8ECA-06A77ABCCFE2 Q37176364-497C71C1-A386-4F9F-988E-D2EA44F12480 Q37199204-4D82902F-0C53-4D2C-9C05-1A81BA4C4D7C Q37463716-C97C822F-6A54-438E-9205-BF4170C80E72 Q37532561-308046D5-93ED-435A-9B4A-8E07081ED77D Q37579579-73D24C74-ED12-4558-B3D0-5876BC25D8D2 Q37625447-D03F23DA-A7CD-472F-A2EB-4CFE535A79E1 Q38009712-24576648-998B-40B2-A67C-D073F59E938A Q38047183-95F205D6-A39B-4BB6-B39A-BF4793EAC910 Q38414010-7E57B90A-3AF4-4A64-BE2A-9A9FAD706C72 Q38425187-41856FD7-AA0F-4110-BD7B-7E08E006F75A Q39791628-55E2761A-D270-48EB-9F35-9035E8962A54 Q39945856-DBFFFC68-DA59-4924-BE11-84005F0C541F Q40165526-06C7E1D4-69B6-4F0D-BA86-90C147B66496 Q42148836-C6F67136-51EF-4ED7-9AAB-FCED76CDE53A Q42966206-49B67BD3-CE0A-454D-93C7-E1246E94F5C7 Q45899252-2A115849-5BF0-4732-9904-1B21B2EBA024 Q47138639-59FE6A0F-4B0E-4F88-A5CF-EF7E6D9A61AE Q47401384-9C42709E-42A3-4FFF-8AE0-296AA1A7DD64 Q48184294-AFEF4020-D87B-478A-BB94-F1BDE4263FE7 Q50285287-310B2311-5517-4923-8024-DA92B4DDC08A Q51423055-5EADD62F-BAA8-404E-AEDE-63078D944D18 Q51565203-7EB300E8-AD22-4AE5-B5CD-103F657CB33B Q53060269-13C123B2-D25C-4A11-A87F-705F8D358A03 Q53771696-0D6790DB-272D-4C9F-B878-FE87E0C3A4D1 Q55384465-FB07F38D-86C6-4271-90F7-87E25233A411

P2860

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

http://www.wikidata.org/entity/Q46212098

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@en

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@nl

type

label

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@en

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@nl

prefLabel

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@en

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@nl

P1433

Q46212098-B71510D7-8385-4AA7-B15E-D8B2129BDA12

P1476

Q46212098-F215E515-BE43-4E33-B033-2321A3037076

P2093

Q46212098-0249E3D3-FDE4-42C4-8510-5BC9098638A7

Q46212098-02FA0711-A1FC-47B6-8D0D-1101126A1AA2

Q46212098-0C6375E0-FF4D-4064-9A12-7EF256CFCA74

Q46212098-1D8BEC58-F3A3-4981-BCEE-F0968EB62130

Q46212098-330D4779-DCAA-4B9A-BCF3-7AAD2A4A0DE3

Q46212098-3832887B-108E-4B80-BE14-7D6B480D7717

Q46212098-586F18EC-1EDE-478D-A690-EE71E980AD68

Q46212098-67366EC7-305C-459C-9345-D07CE6772068

Q46212098-89A96A22-8C65-4041-817E-09E3372A51AE

Q46212098-93D29D5A-7F64-4C28-B20A-E09456924E82

P2860

Q46212098-4634FCE7-9239-4872-A4DA-E3F0A40A8458

Q46212098-7C7A458C-5C90-4F2F-94DE-B52648450408

Q46212098-8585D9E6-3EDF-4403-AF86-F841B4EDC91E

Q46212098-CF0B5B22-2EBC-4498-8213-D07A89E2257D

P304

Q46212098-F493C5D6-AA83-41A2-9188-F3A0E30DBA58

P31

Q46212098-16F0827C-29A2-4F0F-A0C1-0D4FCCF6D694

P356

Q46212098-134A8E84-3BCB-48D1-B972-989B9B1C580E

P433

Q46212098-F1974AE6-61AB-4364-ABEA-C6DEBD1F92C4

P478

Q46212098-2245E001-2A74-481D-A3EF-5AFB7CA63462

P577

Q46212098-B0301082-70BE-4960-B377-8063E7304B0C

P5875

Q46212098-5329EA0B-4D3B-4B10-AB57-986B3EBE06C4

P698

Q46212098-577C5314-7A87-4C7C-B881-D8FD39012C5D

P356

P1433

Journal of Bone and Mineral Research

P1476

RANKL inhibition with osteopro ...... ecture in ovariectomized rats.

@en

P2093

Denise Dwyer

http://www.w3.org/2001/XMLSchema#string

Frank J Asuncion

http://www.w3.org/2001/XMLSchema#string

Hong-Lin Tan

http://www.w3.org/2001/XMLSchema#string

Hua Z Ke

http://www.w3.org/2001/XMLSchema#string

James McCabe

http://www.w3.org/2001/XMLSchema#string

Kelly S Warmington

http://www.w3.org/2001/XMLSchema#string

Marina Stolina

http://www.w3.org/2001/XMLSchema#string

Mario Grisanti

http://www.w3.org/2001/XMLSchema#string

Mauricio Barrero

http://www.w3.org/2001/XMLSchema#string

Michael S Ominsky

http://www.w3.org/2001/XMLSchema#string

P2860

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Osteoprotegerin Reduces the Serum Level of Receptor Activator of NF- B Ligand Derived from Osteoblasts

P304

672-682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1359/JBMR.080109

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227791451

http://www.w3.org/2001/XMLSchema#string

P698

18433301

http://www.w3.org/2001/XMLSchema#string